Issue 2
-
Plenary explores chromosomal instability’s role in cancer treatment
(Clockwise, top left) Samuel F. Bakhoum, MD, PhD, Karlene A. Cimprich, PhD, Stephen P. Jackson, PhD, and David Pellman, PhD, discussed its viability as a novel therapy target.
-
First Clinical Trials Plenary features practice-changing data from phase III trials
Updates on phase III trials came from (clockwise, top left) Matthew J. Matasar, MD, Jessica Hassel, MD, Patrick M. Forde, MBBCh, and Georgina V. Long, PhD, MBBS.
-
Daily Highlights for Sunday, April 11
Program Committee Chair Charles Swanton, MBPhD, FAACR, shares some of his selections from the day’s sessions to help plan your Annual Meeting experience.
-
CD40 agonist primes T-cell response to treat pancreatic cancer, early trial results show
(Clockwise, from top left) Katelyn T. Byrne, PhD, Brett G.M. Hughes, MSci, MBBS, Sanaz N. Ghafouri, MD, Jason Alan Chesney, MD, PhD, and Richard S. Finn, MD, will present during the session.
-
Clarkson Symposium explores stem cells, leukemia, and the niche
Presenters (from left) Sean J. Morrison, PhD, Leonard I. Zon, MD, and Iannis Aifantis, PhD, will also participate in a live panel and Q&A session on Monday on the same topics.
-
Opening Plenary to salute groundbreaking research leading to clinical breakthroughs
Presenters (clockwise, from top left): Jonathan Weissman, PhD, Karen Vousden, PhD, FAACR, Matthew Vander Heiden, MD, PhD, Melissa Davis, PhD, Mark Dawson, MD, PhD, and Zhijan James Chen, PhD.
-
Elite group receives AACR scientific achievement awards and lectureships
The American Association for Cancer Research honored several cancer researchers, physician-scientists, advocates, and policymakers for their achievements during the Annual Meeting.